Until recently, people with type 2 diabetes mellitus (PwT2DM) with poor glycaemic control on oral antidiabetic medication were initiated on insulin therapy. While insulin-based therapies have been efficient in reducing hyperglycaemia, they have also been linked with an increased risk of hypoglycaemia, increased treatment burden, and weight gain. The advent of novel classes of antidiabetic agents, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) presents a significant shift in the T2DM treatment algorithms. These medications are not only efficient in the reduction of glycaemia but are also able to reduce weight and have cardiovascular and renal benefits. PwT2DM on complex insulin regimens can now benefit from therapy simplification, taking advantage of once-daily fixed-ratio combinations (FRC) of basal insulin and glucagon-like peptide-1 receptor agonist. Current evidence suggests that this approach is equally efficient in terms of glycaemic control with the additional benefit of the reduction of body weight, total daily dose of insulin, and the number of insulin injections administered per day with no increase or reduction of hypoglycaemia. The primary aim of this review is to present the current evidence supporting the simplification of complex insulin regimens in PwT2DM with the two currently available FRCs on the market (insulin glargine 100 U/mL and GLP-1 RA lixisenatide [iGlarLixi] or insulin degludec and GLP-1 RA liraglutide [IDegLira]) and to provide a simple clinical practice-oriented algorithm for clinicians based on the currently available evidence.

Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773‐795. PubMed PMC

Guo S, Dai C, Guo M, et al. Inactivation of specific β cell transcription factors in type 2 diabetes. J Clin Invest. 2013;123(8):3305‐3316. PubMed PMC

Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell. 2012;150(6):1223‐1234. PubMed PMC

Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC. β‐Cell mass and turnover in humans: effects of obesity and aging. Diabetes Care. 2013;36(1):111‐117. PubMed PMC

Liu J, Rutten‐Jacobs L, Liu M, Markus HS, Traylor M. Causal impact of type 2 diabetes mellitus on cerebral small vessel disease: a Mendelian randomization analysis. Stroke. 2018;49(6):1325‐1331. PubMed PMC

Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002;25(5):894‐899. PubMed

Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18‐year prospective population‐based study in Finnish subjects. Diabetes Care. 2005;28(12):2901‐2907. PubMed

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient‐centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2012;35(6):1364‐1379. PubMed PMC

Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240‐245. PubMed PMC

Amerzadeh M, Shafiei Kisomi Z, Senmar M, Khatooni M, Hosseinkhani Z, Bahrami M. Self‐care behaviors, medication adherence status, and associated factors among elderly individuals with type 2 diabetes. Sci Rep. 2024;14(1):19118. PubMed PMC

Wang H, Zhou Y, Wang Y, et al. Basal insulin reduces glucose variability and Hypoglycaemia compared to premixed insulin in type 2 diabetes patients: a study based on continuous glucose monitoring systems. Front Endocrinol. 2022;13:791439. PubMed PMC

Gómez AM, Henao‐Carillo DC, Taboada L, et al. Clinical factors associated with high glycemic variability defined by coefficient of variation in patients with type 2 diabetes. Med Devices (Auckl). 2021;14:97‐103. PubMed PMC

Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012;28(2):287‐300. PubMed PMC

Jódar E, Romera I, Wang Q, Roche SL, García‐Pérez L‐E. Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: post hoc analyses of randomized clinical trials. Diabetes Obes Metab. 2022;24(4):631‐640. PubMed PMC

Ajjan RA. The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control. Diabetes Obes Metab. 2024;26(S7):3‐16. PubMed PMC

American Diabetes Association Professional Practice . Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes—2025. Diabetes Care. 2024;48:S181‐S206. PubMed PMC

Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2022;45(11):2753‐2786. PubMed PMC

Klein KR, Clemmensen KKB, Fong E, Olsen S, Abrahamsen T, Lingvay I. Occurrence of gastrointestinal adverse events upon GLP‐1 receptor agonist initiation with concomitant metformin use: a post hoc analysis of LEADER, STEP 2, SUSTAIN‐6, and PIONEER 6. Diabetes Care. 2023;47(2):280‐284. PubMed PMC

Chang TI, Park H, Kim DW, et al. Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. Sci Rep. 2020;10(1):18964. PubMed PMC

Idil E, Aydin AE, Ates Bulut E, Isik AT. Rationally decreasing the number of drugs seems to be a useful therapeutic approach in older adults: 6‐month follow‐up study. Arch Gerontol Geriatr. 2021;96:104472. PubMed

Sanofi . Summary of product characteristics—Suliqua. 2024. https://www.ema.europa.eu/en/documents/product‐information/suliqua‐epar‐product‐information_en.pdf

Hilgenfeld R, Seipke G, Berchtold H, Owens DR. The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs. 2014;74(8):911‐927. PubMed PMC

Meier JJ. GLP‐1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728‐742. PubMed

Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a Titratable fixed‐ratio combination of insulin glargine plus Lixisenatide, versus insulin glargine and Lixisenatide Monocomponents in type 2 diabetes inadequately controlled on Oral agents: the LixiLan‐O randomized trial. Diabetes Care. 2016;39(11):2026‐2035. PubMed

Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a Titratable fixed‐ratio combination of insulin glargine plus Lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan‐L randomized trial. Diabetes Care. 2016;39(11):1972‐1980. PubMed

Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP‐1 RA in type 2 diabetes inadequately controlled by GLP‐1 RA and Oral Antihyperglycemic therapy: the LixiLan‐G randomized clinical trial. Diabetes Care. 2019;42(11):2108‐2116. PubMed

Ishii H, Kamiya H, Takahashi Y, Morimoto Y, Yabe D. Quality of life in Japanese people with type 2 diabetes switching from multiple daily insulin injections to once‐daily iGlarLixi: SIMPLIFY Japan. Diabetes Ther. 2024;15(11):2381‐2400. PubMed PMC

NovoNordisk . Xultophy Summary of Product Characteristics. 2020. https://www.medicines.org.uk/emc/product/3469/smpc

Heise T, Hövelmann U, Nosek L, Hermanski L, Bøttcher SG, Haahr H. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11(8):1193‐1201. PubMed

Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926‐2933. PubMed

Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal‐bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009‐1016. PubMed

Gough SCL, Bode B, Woo V, et al. Efficacy and safety of a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open‐label, randomised, 26‐week, treat‐to‐target trial in insulin‐naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885‐893. PubMed

Gough SCL, Bode BW, Woo VC, et al. One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial. Diabetes Obes Metab. 2015;17(10):965‐973. PubMed PMC

Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34(2):189‐196. PubMed PMC

Watada H, Ross Agner BF, Doshi A, Bardtrum L, Ranthe MF, Billings LK. IDegLira improves glycemic control in Japanese patients with uncontrolled type 2 diabetes on premixed insulin therapy. Diabetes Ther. 2020;11(1):331‐339. PubMed PMC

Marso SP, Daniels GH, Brown‐Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311‐322. PubMed PMC

Westergaard L, Alifrangis L, Buckley ST, et al. Pharmacokinetic properties of a once‐weekly fixed‐ratio combination of insulin Icodec and Semaglutide compared with separate Administration of each Component in individuals with type 2 diabetes mellitus. Clin Drug Investig. 2024;44(11):849‐861. PubMed PMC

Lingvay I, Benamar M, Chen L, et al. Once‐weekly IcoSema versus once‐weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia. 2025;68(4):739‐751. PubMed PMC

Harreiter J, Kosi‐Trebotic L, Lukas A, et al. Switch to combined GLP1 receptor agonist Lixisenatide with basal insulin glargine in poorly controlled T2DM patients with premixed insulin therapy: a clinical observation and pilot study in nine patients. Diabetes Ther. 2017;8(3):683‐692. PubMed PMC

Miya A, Nakamura A, Miyoshi H, et al. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial. J Diabetes Investig. 2018;9(1):119‐126. PubMed PMC

Novodvorský P, Thieme L, Laňková I, et al. The IDEAL (insulin therapy DE‐intensificAtion with iglarLixi) randomised controlled trial‐study design and protocol. Diabetes Ther. 2024;15(6):1461‐1471. PubMed PMC

Novodvorský P, Thieme L, Laňková I, et al. 60th EASD annual meeting of the European Association for the Study of diabetes. Diabetologia. 2024;67(1):808. PubMed

Zizka O, Novodvorsky P, Thieme L, et al. ATTD 2025 Oral abstracts. Diabetes Technol Ther. 2025;27(S2):OP090.

Novodvorsky P, Thieme L, Lankova I, et al. 782‐P: insulin therapy Deintensification with iGlarLixi—the IDEAL randomized controlled trial. Diabetes. 2024;73(Supplement_1):782. PubMed PMC

Haluzík M, Cypryk K, Alvarez A, et al. Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: the soli‐SWITCH study. Diabetes Obes Metab. 2025;27(5):2730‐2739. PubMed PMC

Rosenstock J, Emral R, Sauque‐Reyna L, et al. Advancing therapy in suboptimally controlled basal insulin–treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care. 2021;44(10):2361‐2370. PubMed PMC

Price H, Blüher M, Prager R, et al. Use and effectiveness of a fixed‐ratio combination of insulin degludec/liraglutide (IDegLira) in a real‐world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab. 2018;20(4):954‐962. PubMed PMC

Taybani Z, Bótyik B, Katkó M, Gyimesi A, Várkonyi T. Simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes. Diabetes Ther. 2019;10(5):1869‐1878. PubMed PMC

Taybani ZJ, Bótyik B, Gyimesi A, Katkó M, Várkonyi T. One‐year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes. Endocr Diabetes & Metab. 2023;6(1):e390. PubMed PMC

Martinka E, Dravecká I, Tkáč I. Switching from multiple insulin injections to a fixed combination of Degludec and Liraglutide in patients with type 2 diabetes mellitus: results from the Simplify study after 6 months. Diabetes Ther. 2023;14(9):1503‐1515. PubMed PMC

Watada H, Kaneko S, Komatsu M, et al. Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial. Diabetes Obes Metab. 2019;21(12):2694‐2703. PubMed PMC

Bostandzic AD, Beslic VK, Surkovic I, et al. IDegLira improves metabolic control in patients with type 2 diabetes previously treated with premix insulin. Med Arch. 2022;76(2):96‐100. PubMed PMC

Guo C, Lu Y. Early conversion of intensive insulin therapy to IDegLira demonstrates higher efficacy and safety in reducing fasting blood glucose and HbA1c in T2DM patients. Diabetes Metab Syndr Obes. 2024;17:3217‐3226. PubMed PMC

Egede LE, Bogdanov A, Fischer L, Da Rocha Fernandes JD, Kallenbach L. Glycemic control among patients newly prescribed IDegLira across prior therapy group in US real‐world practice. Diabetes Ther. 2020;11(7):1579‐1589. PubMed PMC

Fadini GP, Buzzetti R, Pitocco D, et al. IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study. Diabetes Obes Metab. 2024;26(5):1746‐1756. PubMed

Zenari L, Da Porto A, De Moliner L, et al. Real‐World Evaluation of Glycemic Outcomes and Extra‐Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira). Diabetes Ther. 2021;12(1):197‐209. PubMed PMC

Tramunt B, Disse E, Chevalier N, et al. Initiation of the fixed combination IDegLira in patients with type 2 diabetes on prior injectable therapy: insights from the EASY French real‐world study. Diabetes Ther. 2022;13(11–12):1947‐1963. PubMed PMC

Rizza S, Piciucchi G, Mavilio M, et al. Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life. Biomed Pharmacother. 2021;144:112341. PubMed

Di Loreto C, Celleno R, Piastrella L, Del Sindaco P. IDegLira fixed‐ratio combination in the real world: a retrospective observational single‐center Italian experience. Eur Rev Med Pharmacol Sci. 2020;24(20):10671‐10679. PubMed

Giugliano D, Longo M, Caruso P, et al. Feasibility of simplification from a basal‐bolus insulin regimen to a fixed‐ratio formulation of basal insulin plus a GLP‐1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, Pragmatic Trial. Diabetes Care. 2021;44(6):1353‐1360. PubMed PMC

Giugliano D, Longo M, Scappaticcio L, et al. BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes. Endocrine. 2024;83(2):399‐404. PubMed PMC

Rodriguez P, San Martin VT, Pantalone KM. Therapeutic inertia in the Management of Type 2 diabetes: a narrative review. Diabetes Ther. 2024;15(3):567‐583. PubMed PMC

Gavin JR, Abaniel RM, Virdi NS. Therapeutic inertia and delays in insulin intensification in type 2 diabetes: a literature review. Diabetes Spectr. 2023;36(4):379‐384. PubMed PMC

Escalada J, Orozco‐Beltran D, Morillas C, et al. Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: a survey research. Diabetes Res Clin Pract. 2016;122:46‐53. PubMed